Why the study?
To evaluate the ability of the platelet-to-hemoglobin ratio to predict mortality and disease severity in patients with acute pulmonary embolism.
Does the platelet-to-hemoglobin ratio predict mortality and disease severity in patients with acute pulmonary embolism?
Does the platelet-to-hemoglobin ratio predict mortality and disease severity in patients with acute pulmonary embolism?
The platelet-to-hemoglobin ratio is a novel, easily accessible biomarker that independently predicts disease severity and short-term mortality in acute pulmonary embolism.
Answers are grounded in this paper and cite their sources.
PHR may aid APE severity stratification; this Level 3 cohort association leaves open prospective validation before clinical adoption.
Background: We investigated the ability of the platelet-to-hemoglobin ratio (PHR) to predict mortality and disease severity in patients with acute pulmonary embolism (APE). Materials & methods: The severity of APE was classified as massive (high risk), submassive (intermediate risk) or nonmassive (low risk). PHR is defined as platelet count/hemoglobin count. Results: PHR was significantly higher in patients with massive APE, and this elevation showed a gradual increase from the nonmassive group to the massive group (p < 0.001). In-hospital and 1-month mortality were higher in patients with high PHR values. PHR was an independent risk factor for the development of massive APE (odds ratio: 1.014; 95% CI: 1.011–1.017; p = 0.009). Conclusion: PHR values predicted massive APE and were an independent predictor of mortality in APE.
No takes yet. Share an insight, caveat, or question.
Özbeyaz et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: